ZyVersa Therapeutics (ZVSA) eyes deep cost cuts, asset sales and possible ‘going dark’

Q: What cost-cutting measures is ZyVersa Therapeutics (ZVSA) pursuing?

ZyVersa’s Board and management are pursuing cost-cutting measures including executive pay reductions, potential asset divestitures , possible headcount reductions , and ways to decrease public-company expenses.

Q: Is ZyVersa Therapeutics (ZVSA) considering going dark from SEC reporting?

ZyVersa is considering “going dark” by suspending its periodic reporting obligations under Sections 13(a) and 15(d) of the Exchange Act, potentially using Rule 12h-3 to reduce public-company expenses.

Q: How are ZyVersa Therapeutics’ (ZVSA) executives contributing to cost savings?

CEO Stephen Glover and CFO Peter Wolfe have each voluntarily agreed to reduced compensation , aiming to support the company during a period of limited cash resources and improve balance sheet flexibility.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

ZyVersa Therapeutics, Inc. reported that on July 8, 2026, independent director Min Chul Park, Ph.D. resigned from the Board, the Compensation Committee, and the Nominating and Corporate Governance Committee for personal reasons, with no disagreement related to operations, policies, or practices. The company’s leadership has begun implementing and evaluating cost-cutting measures while seeking to raise capital. The CEO and CFO have voluntarily accepted reduced compensation to conserve cash and increase balance sheet flexibility. Potential additional actions include divesting or selling the VAR 200 or IC 100 product candidates, reducing employee headcount, and decreasing public-company expenses, which may include “going dark” by suspending reporting obligations under Sections 13(a) and 15(d) via Rule 12h-3. ZyVersa is also considering broader strategic alternatives such as a sale of the company or its assets, or a restructuring or reorganization, aiming to extend operations while pursuing new financing.

Positive

None.

Negative

Company exploring divestiture of VAR 200 and IC 100, which could reduce future product pipeline if sold for short-term liquidity.
Considering headcount reductions and other cost cuts, indicating significant pressure on operating resources and potential impact on capabilities.
Evaluating going dark under Rule 12h-3, which would suspend periodic SEC reporting and reduce public transparency for shareholders.
Board and management are considering sale, restructuring, or reorganization, signaling that the current capital structure and operations may not be sustainable.

Insights

Director exit and possible asset sales signal financial strain at ZyVersa.

The resignation of independent director Min Chul Park, Ph.D. is described as for personal reasons and not due to disagreements, which limits immediate governance concerns. However, the broader context of aggressive cost-cutting and capital needs is more significant for shareholders.

Management has already taken voluntary compensation reductions and is evaluating potentially selling key product candidates VAR 200 and IC 100, reducing headcount, and cutting public-company costs, including possibly “going dark” under Rule 12h-3. These are characteristic of a company facing constrained liquidity and exploring multiple levers to preserve cash.

In addition, ZyVersa is weighing strategic alternatives such as a sale of the company or its assets and possible restructuring or reorganization. The company states that savings from any adopted measures, together with any capital raised, may allow operations to continue while further financing is pursued, underscoring that its current financial position requires active remediation.

8-K Event Classification

2 items: 5.02, 8.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Director resignation date: July 8, 2026 Report signature date: July 10, 2026 Common stock market: OTCQB Venture Market

3 metrics

Director resignation date July 8, 2026 Date Min Chul Park, Ph.D. notified the Board of his resignation

Report signature date July 10, 2026 Date ZyVersa’s CEO Stephen Glover signed the report

Common stock market OTCQB Venture Market Market where ZyVersa’s common stock is quoted under symbol ZVSA

Key Terms

going dark, Rule 12h-3, emerging growth company, OTCQB® Venture Market, +1 more

5 terms

going dark regulatory

"including possibly “going dark” by suspending its obligations to file its current and periodic reports"

Going dark describes when a publicly traded company stops filing regular financial and other reports with securities regulators, often by deregistering its shares or meeting an exemption that frees it from those disclosure rules. For investors it matters because the company becomes like a business that no longer posts progress updates: there is less public information, trading can become thinner or harder, and valuing or selling shares can be riskier and more uncertain.

Rule 12h-3 regulatory

"pursuant to Rule 12h-3 promulgated thereunder"

emerging growth company regulatory

"Emerging growth company (1)"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

OTCQB® Venture Market market

"The Company’s common stock is quoted on the OTCQB® Venture Market"

restructuring or reorganization financial

"including, but not limited to sale of the Company or its assets, or restructuring or reorganization"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/10/2026 - 04:31 PM Accepted by SEC EDGAR 07/10/2026 - 04:30 PM

FAQ

Why did director Min Chul Park resign from ZyVersa Therapeutics (ZVSA)?

Dr. Min Chul Park resigned from ZyVersa’s Board and key committees for personal reasons. The company states his resignation was not due to any disagreement regarding operations, policies, or practices.

What cost-cutting measures is ZyVersa Therapeutics (ZVSA) pursuing?

ZyVersa’s Board and management are pursuing cost-cutting measures including executive pay reductions, potential asset divestitures, possible headcount reductions, and ways to decrease public-company expenses.

Is ZyVersa Therapeutics (ZVSA) considering going dark from SEC reporting?

ZyVersa is considering “going dark” by suspending its periodic reporting obligations under Sections 13(a) and 15(d) of the Exchange Act, potentially using Rule 12h-3 to reduce public-company expenses.

What strategic alternatives is ZyVersa Therapeutics (ZVSA) evaluating?

ZyVersa is evaluating alternatives to maximize shareholder value, including a sale of the company or its assets, or a possible restructuring or reorganization, alongside ongoing cost-reduction efforts.

How are ZyVersa Therapeutics’ (ZVSA) executives contributing to cost savings?

CEO Stephen Glover and CFO Peter Wolfe have each voluntarily agreed to reduced compensation, aiming to support the company during a period of limited cash resources and improve balance sheet flexibility.

What is ZyVersa Therapeutics (ZVSA) aiming to achieve with these measures?

ZyVersa expects that savings from cost-reduction measures, together with any capital raised, may allow it to continue operations while it seeks additional financing to stabilize finances and operations.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 8, 2026

ZYVERSA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41184

86-2685744

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2436 N Federal Hwy, Suite 466

Lighthouse Point, Florida

33064

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code:

(754) 231-1688

	Not Applicable
	(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(g) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ZVSA		(1)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

(1) The Company’s common stock is quoted on the OTCQB® Venture Market under the symbol “ZVSA.”

Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Min Chul Park, Ph.D.

On July 8, 2026, Min Chul Park, Ph.D., notified the Board of Directors (the “Board”) of ZyVersa Therapeutics, Inc. (the “Company”) of his intention to resign from his Board positions as an independent director, member of the Compensation Committee of the Board, and member of the Nominating and Corporate Governance Committee of the Board. Dr. Park’s resignation has been accepted by the Board, effective immediately. Dr. Park’s resignation was due to personal reasons and not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

Item 8.01 Other Events.

The Board and management of the Company have commenced, and are continuing to explore, certain cost-cutting measures to maximize the Company’s available resources while it seeks to raise capital. For example, Stephen Glover and Peter Wolfe, the Company’s Chief Executive Officer and Chief Financial Officer, respectively, each voluntarily agreed to accept reduced compensation to support the Company during a period of limited cash resources and to provide the Company with greater balance sheet flexibility.

In addition, measures being considered include:

	●	Divesting or selling the Company’s VAR 200 or IC 100 product candidates.
	●	Reducing employee headcount to focus on core services and support, with corresponding reduced costs.
	●	Considering ways to decrease public company expenses, including possibly “going dark” by suspending its obligations to file its current and periodic reports required by Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12h-3 promulgated thereunder.

In addition, the Company will continue to consider other ways to maximize shareholder value, including, but not limited to sale of the Company or its assets, or restructuring or reorganization, among other alternatives.

The Company expects that any savings generated from such cost-reduction activities as are ultimately adopted, along with any capital raise, may enable the Company to continue operations while the Company continues to seek new sources of financing to stabilize its finances and operations.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Current Report on Form 8-K (“Form 8-K”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s common cost-cutting measures. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks, uncertainties and other important factors, including those factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by the Company’s Quarterly Report on Form 10-Q for the quarter ended March 30, 2026, in each case as filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form 8-K. Any forward-looking statements speak only as of the date of this Form 8-K and are based on information available to the Company as of the date of this Form 8-K, and the Company assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 10, 2026	ZYVERSA THERAPEUTICS, INC.

	/s/ Stephen Glover
	Stephen Glover
	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents